


ABSTRACT OF THE DISCLOSURE

This invention relates to compounds which are generally muscarinic M2/M3
5 receptor antagonists and which are represented by Formula I:



wherein X, Y, and Z are O, S or NR⁵, and the other substituents are as defined in the
10 specification; and prodrugs, individual isomers, racemic or non-racemic mixtures of
isomers, and pharmaceutically acceptable salts or solvates thereof. The invention
further relates to pharmaceutical compositions containing such compounds and
methods for their use as therapeutic agents.

15